source
- FDA advisory panel votes 9-3 against Capricor's Duchenne therapy deramiocelDuring an FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting, reviewers focused on the Phase 3 HOPE-3 trial's secondary cardiac endpoint and described the data as very fragile. The…
- Biogen beats revenue expectations, lifts investor confidence with 3% sales riseBiogen reported $2.7 billion in revenue for the April‑June quarter, a 3% increase year over year, surpassing analysts' consensus estimate of $2.5 billion. Adjusted earnings per share came in at $3.…